Embed Size (px)
DESCRIPTION
Drug Innovation 2.0 – Why we Need Knowledge Metrics for Democratic Action In this presentation we share three current challenges for innovation in drug design. 1) Group dynamics – Scientific collaboration typically occurs through networks. Inefficient collaboration and networking can lead to tunnel vision; innovation opportunities through more distant networks may be overlooked. Knowledge metrics can encourage new and productive networks, by appropriately rewarding contributing network members. 2) Information overload – Information and knowledge are not the same thing. We have too much (unstructured) information and we lack the time required to structure this information into knowledge. Knowledge metrics can encourage the ranking, structuring, and accessing of information on a reward-per-use basis. 3) Data silos – Data silos caused by technical or license hurdles, can reduce the number of efficient collaboration options. Knowledge metrics should clearly reward barrier-breaking and silo-bridging efforts, and favor new and diverse over redundant information…Drug designers, lawyers and computer scientists have a unique opportunity to take on these challenges – drug innovation 2.0!
Citation preview
Drug Innovation 2.0Why we Need Knowledge Metrics for Democratic Action
Joerg Kurt Wegner
2009
Tibotec
J.K. Wegner, 2009, Tibotec
You
information
We want to innovate with novel information
J.K. Wegner, 2009, Tibotec
Innovate with … … knowledge = people + information
knowledge you need, but do not have, yet !
people + information
You
J.K. Wegner, 2009, Tibotec
You
Friend of a Friend
TopicGuru
For getting knowledge (=people+information) you needknowledge = people + informationEnable this by collaborating with your peers !
people information
J.K. Wegner, 2009, Tibotec
Use metrics for improving your peer collaboration
Knowledge
=people+information
Need
Knowledge creation cycle
J.K. Wegner, 2009, Tibotec
Peers are the metric ! Embrace and use “web 2.0” !
Filter
Content
J.K. Wegner, 2009, Tibotec
Drug Innovation 2.0 challenges
Negative group dynamics
Information overload
Data silos
J.K. Wegner, 2009, Tibotec
People are scared ?Use a contribution revision for helping people
Ensure compliance
Educate contributors
§
J.K. Wegner, 2009, Tibotec
Are we hiding knowledge (=people+information)?Create knowledge and measure progress!
After information makes sense do not hide it in a silo, e.g. eMail
• Share content - Three paragraph text • Filter/organize - Hard to find information• Compete – Make contributions transparent
J.K. Wegner, 2009, Tibotec
Improve knowledge(people+information) collaboration
Stop shouting from skyscrapers,
allow “people-centric” feedback.
Ensure there is a driving oligarchy,
e.g. people with “knowledge sharing” as
job objective.
J.K. Wegner, 2009, Tibotec
Drug Innovation 2.0 challenges
Negative group dynamics• Peer cycles are creating innovative knowledge• Support people with revisioning• Improve your knowledge(=people+information) creation factor • Knowledge collaboration must be measured and improved
Information overload
Data silos
The knowledge gap is increasing,caused by information overload !
0
250000
500000
750000
1000000
J.K. Wegner, 2009, Tibotec
knowledgegap
information
knowledge
source: NCBI PubMed
Year
Articles
J.K. Wegner, 2009, Tibotec
Information overload and a knowledge gapare a major risk
41% / day managing e-mail
25% / day finding information
This costs ~$900 billion per year in
lowered employee productivity and
reduced innovation.
J.K. Wegner, 2009, Tibotec
Knowledge workers have too much information, do too little sharing. Stop this ! Leverage !
Keeping nothing does not cost anything?
But you can not control what you do not know!
Keeping is a challenge, but leveraging helps.
Which metric helps you optimize?
J.K. Wegner, 2009, Tibotec
Drug Innovation 2.0 challenges
Negative group dynamics
Information overload• Too much information/work for a single person• Leverage knowledge collaborations by measuring and
improving knowledge(=people+information) growth
Data silos
J.K. Wegner, 2009, Tibotec
Aspirin was found as drug in 1899. At that time, the puzzle was simple.
Today, information is spread over growing silos.Drug puzzles are complex, collaboration is key!
J.K. Wegner, 2009, Tibotec
Regulations
Patients
-OMICS
Last 10 years
x5from 100k
to 500k
Literature
Last 10 years
x1.6from 500k
to 800k
J.K. Wegner, 2009, Tibotec
Defragmenting data silos is key foraccelerating research
Standardization, e.g. for Biobanking data
People must be able to access people silos• e.g. Twitter
Integration
J.K. Wegner, 2009, Tibotec
Legal barriers to data silos ? Get over it, we need to build bridges !
Private-Public
partnership
Drug Innovation 2.0 challenges
Negative group dynamics
Information overload
Data silos• Not using knowledge, does not help patients !• Build legal data silo bridges for knowledge(people+information)• Measure and improve silo bridging efforts (defragmentation)
J.K. Wegner, 2009, Tibotec
J.K. Wegner, 2009, Tibotec
Drug Innovation 2.0 – Measure and improve !knowledge = people + information
Negative group dynamicsEncourage people by measuring efficiency and helping them to learn, to compete, to share, and to build trust.
Information overloadNot keeping is easy!
Keeping is a challenge, but crowd-sourcing, “people-need”, and “people-centric” solutions can create knowledge networks.
Data silosThere are many challenges: standardization, semantics, security, integration, and legal aspects.
Helping patients requires building silo bridges !
